Cytosine methyltransferases as tumor markers

Current Genomics

Volumn 11, Issue 8, 2010, Pages 568-577

  Pavlopoulou, Athanasia ^a,b   Kossida, Sophia ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Biomarkers; Cancer; Chromatin modification; CpG methylation; DNMTs; Epigenetic therapy; Oncogenes; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPIGALLOCATECHIN GALLATE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE METHYLTRANSFERASE; METHYL CPG BINDING PROTEIN 2; MG 98; MICRORNA; N PHTHALOYLTRYPTOPHAN; TUMOR MARKER; ZEBULARINE;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL TRANSFORMATION; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE SILENCING; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN;

EID: 78649999993     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920210793360916     Document Type: Article

References (129)

1. Baylin, S. B.; Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer, 2006, 6, 107-116.
2. Lohrum, M.; Stunnenberg, H. G.; Logie, C. The new frontier in cancer research: deciphering cancer epigenetics. Int. J. Biochem. Cell Biol., 2007, 39, 1450-1461.
3. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell, 2007, 128, 683-692.
4. Hermann, A.; Gowher, H.; Jeltsch, A. Biochemistry and biology of mammalian DNA methyltransferases. Cell. Mol. Life Sci., 2004, 61, 2571-2587.
5. Esteller, M.; Corn, P. G.; Baylin, S. B.; Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 2001, 61, 3225-3229.
6. Bestor, T. H. The DNA methyltransferases of mammals. Hum. Mol. Genet., 2000, 9, 2395-2402.
7. Baylin, S. B.; Esteller, M.; Rountree, M. R.; Bachman, K. E.; Schuebel, K.; Herman, J. G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet., 2001, 10, 687-692.
8. Nephew, K. P.; Huang, T. H. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett., 2003, 190, 125-133.
9. Bird, A. CpG islands as gene markers in the vertebrate nucleus. Trends Genet., 1987, 3, 342-347.
10. Takai, D.; Jones, P. A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA, 2002, 99, 3740-3745.
11. Kass, S. U.; Pruss, D.; Wolffe, A. P. How does DNA methylation repress transcription? Trends Genet., 1997, 13, 444-449.
12. Wade, P. A.; Wolffe, A. P. ReCoGnizing methylated DNA. Nat. Struct. Biol., 2001, 8, 575-577.
13. Dhasarathy, A.; Wade, P. A. The MBD protein family-reading an epigenetic mark? Mutat. Res., 2008, 647, 39-43.
14. Hendrich, B.; Bird, A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell Biol., 1998, 18, 6538-6547.
15. Nan, X.; Campoy, F. J.; Bird, A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell, 1997, 88, 471-481.
16. Bird, A. P.; Wolffe, A. P. Methylation-induced repression--belts, braces, and chromatin. Cell, 1999, 99, 451-454.
17. Hendrich, B.; Tweedie, S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet., 2003, 19, 269-277.
18. Wade, P. A. Methyl CpG-binding proteins and transcriptional repression. Bioessays, 2001, 23, 1131-1137.
19. Knoepfler, P. S.; Eisenman, R. N. Sin meets NuRD and other tails of repression. Cell, 1999, 99, 447-450.
20. Ballestar, E.; Esteller, M. The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. Prog. Mol. Subcell. Biol., 2005, 38, 169-181.
21. Bender, J. Chromatin-based silencing mechanisms. Curr. Opin. Plant Biol., 2004, 7, 521-526.
22. Woodcock, C. L. Chromatin architecture. Curr. Opin. Struct. Biol., 2006, 16, 213-220.
23. Garcia, B. A.; Shabanowitz, J.; Hunt, D. F. Characterization of histones and their post-translational modifications by mass spectrometry. Curr. Opin. Chem. Biol., 2007, 11, 66-73.
24. Roth, S. Y.; Denu, J. M.; Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem., 2001, 70, 81-120.
25. Mellor, J. Dynamic nucleosomes and gene transcription. Trends Genet, 2006, 22, 320-329.
26. Jenuwein, T. The epigenetic magic of histone lysine methylation FEBS J., 2006, 273, 3121-3135.
27. Schlesinger, Y.; Straussman, R.; Keshet, I.; Farkash, S.; Hecht, M.; Zimmerman, J.; Eden, E.; Yakhini, Z.; Ben-Shushan, E.; Reubinoff, B. E.; Bergman, Y.; Simon, I.; Cedar, H. Polycombmediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet., 2007, 39, 232-236.
28. Jones, P. L.; Veenstra, G. J.; Wade, P. A.; Vermaak, D.; Kass, S. U.; Landsberger, N.; Strouboulis, J.; Wolffe, A. P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet., 1998, 19, 187-191.
29. Nan, X.; Ng, H. H.; Johnson, C. A.; Laherty, C. D.; Turner, B. M.; Eisenman, R. N.; Bird, A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 1998, 393, 386-389.
30. Fuks, F.; Hurd, P. J.; Wolf, D.; Nan, X.; Bird, A. P.; Kouzarides, T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem., 2003, 278, 4035-1040.
31. Harikrishnan, K. N.; Chow, M. Z.; Baker, E. K.; Pal, S.; Bassal, S.; Brasacchio, D.; Wang, L.; Craig, J. M.; Jones, P. L.; Sif, S.; El-Osta, A. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet., 2005, 37, 254-264.
32. Ng, H. H.; Zhang, Y.; Hendrich, B.; Johnson, C. A.; Turner, B. M.; Erdjument-Bromage, H.; Tempst, P.; Reinberg, D.; Bird, A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet., 1999, 23, 58-61.
33. Wade, P. A.; Gegonne, A.; Jones, P. L.; Ballestar, E.; Aubry, F.; Wolffe, A. P. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet., 1999, 23, 62-66.
34. Zhang, Y.; Ng, H. H.; Erdjument-Bromage, H.; Tempst, P.; Bird, A.; Reinberg, D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev., 1999, 13, 1924-1935.
35. Prokhortchouk, A.; Hendrich, B.; Jorgensen, H.; Ruzov, A.; Wilm, M.; Georgiev, G.; Bird, A.; Prokhortchouk, E. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev., 2001, 15, 1613-1618.
36. Yoon, H. G.; Chan, D. W.; Huang, Z. Q.; Li, J.; Fondell, J. D.; Qin, J.; Wong, J. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J., 2003, 22, 1336-1346.
37. Zhang, J.; Kalkum, M.; Chait, B. T.; Roeder, R. G. The N-CoRHDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol. Cell, 2002, 9, 611-623.
38. Jepsen, K.; Rosenfeld, M. G. Biological roles and mechanistic actions of co-repressor complexes. J. Cell Sci., 2002, 115, 689-698.
39. Yoon, H. G.; Chan, D. W.; Reynolds, A. B.; Qin, J.; Wong, J. NCoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol. Cell, 2003, 12, 723-734.
40. Pandolfi, P. P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum. Mol. Genet., 2001, 10, 769-775.
41. Gibbons, R. J.; McDowell, T. L.; Raman, S.; O'Rourke, D. M.; Garrick, D.; Ayyub, H.; Higgs, D. R. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat. Genet., 2000, 24, 368-371.
42. Dennis, K.; Fan, T.; Geiman, T.; Yan, Q.; Muegge, K. Lsh, a member of the SNF2 family, is required for genome-wide methylation. Genes Dev., 2001, 15, 2940-2944.
43. Esteller, M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 629-656.
44. Baylin, S.; Bestor, T. H. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell, 2002, 1, 299-305.
45. Feinberg, A. P.; Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer, 2004, 4, 143-153.
46. Knudson, A. G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer, 2001, 1, 157-162.
47. Herman, J. G.; Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 2003, 349, 2042-2054.
48. Baylin, S. B.; Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet., 2000, 16, 168-174.
49. Sherr, C. J. Cancer cell cycles. Science, 1996, 274, 1672-1677.
50. Xu, C. F.; Solomon, E. Mutations of the BRCA1 gene in human cancer. Semin. Cancer Biol., 1996, 7, 33-40.
51. Burbee, D. G.; Forgacs, E.; Zochbauer-Muller, S.; Shivakumar, L.; Fong, K.; Gao, B.; Randle, D.; Kondo, M.; Virmani, A.; Bader, S.; Sekido, Y.; Latif, F.; Milchgrub, S.; Toyooka, S.; Gazdar, A. F.; Lerman, M. I.; Zabarovsky, E.; White, M.; Minna, J. D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst., 2001, 93, 691-699.
52. Jeronimo, C.; Usadel, H.; Henrique, R.; Oliveira, J.; Lopes, C.; Nelson, W. G.; Sidransky, D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst., 2001, 93, 1747-1752.
53. Issa, J. P.; Ottaviano, Y. L.; Celano, P.; Hamilton, S. R.; Davidson, N. E.; Baylin, S. B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet., 1994, 7, 536-540.
54. Laird, P. W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer, 2003, 3, 253-266.
55. Sidransky, D. Emerging molecular markers of cancer. Nat. Rev. Cancer, 2002, 2, 210-9.
56. Costello, J. F.; Fruhwald, M. C.; Smiraglia, D. J.; Rush, L. J.; Robertson, G. P.; Gao, X.; Wright, F. A.; Feramisco, J. D.; Peltomaki, P.; Lang, J. C.; Schuller, D. E.; Yu, L.; Bloomfield, C. D.; Caligiuri, M. A.; Yates, A.; Nishikawa, R.; Su Huang, H.; Petrelli, N. J.; Zhang, X.; O'Dorisio, M. S.; Held, W. A.; Cavenee, W. K.; Plass, C. Aberrant CpG-island methylation has non-random and tumourtype-specific patterns. Nat. Genet., 2000, 24, 132-138.
57. Herman, J. G.; Graff, J. R.; Myohanen, S.; Nelkin, B. D.; Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 1996, 93, 9821-9826.
58. Eads, C. A.; Danenberg, K. D.; Kawakami, K.; Saltz, L. B.; Blake, C.; Shibata, D.; Danenberg, P. V.; Laird, P. W. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res., 2000, 28, E32.
59. Gitan, R. S.; Shi, H.; Chen, C. M.; Yan, P. S.; Huang, T. H. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res., 2002, 12, 158-164.
60. Herman, J. G.; Umar, A.; Polyak, K.; Graff, J. R.; Ahuja, N.; Issa, J. P.; Markowitz, S.; Willson, J. K.; Hamilton, S. R.; Kinzler, K. W.; Kane, M. F.; Kolodner, R. D.; Vogelstein, B.; Kunkel, T. A.; Baylin, S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 1998, 95, 6870-6875.
61. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S. N.; Hidalgo, O. F.; Vanaclocha, V.; Baylin, S. B.; Herman, J. G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343, 1350-1354.
62. Verma, M.; Srivastava, S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol., 2002, 3, 755-763.
63. Colot, V.; Rossignol, J. L. Eukaryotic DNA methylation as an evolutionary device. Bioessays, 1999, 21, 402-411.
64. Yoder, J. A.; Walsh, C. P.; Bestor, T. H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet., 1997, 13, 335-340.
65. Walsh, C. P.; Chaillet, J. R.; Bestor, T. H. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat. Genet., 1998, 20, 116-117.
66. Yoder, J. A.; Soman, N. S.; Verdine, G. L.; Bestor, T. H. DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. J. Mol. Biol., 1997, 270, 385-395.
67. Robertson, K. D. DNA methylation, methyltransferases, and cancer. Oncogene, 2001, 20, 3139-3155.
68. Pihan, G. A.; Wallace, J.; Zhou, Y.; Doxsey, S. J. Centrosome abnormalities and chromosome instability occur together in preinvasive carcinomas. Cancer Res., 2003, 63, 1398-1404.
69. Jeanpierre, M.; Turleau, C.; Aurias, A.; Prieur, M.; Ledeist, F.; Fischer, A.; Viegas-Pequignot, E. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Hum. Mol. Genet., 1993, 2, 731-735.
70. Ji, W.; Hernandez, R.; Zhang, X. Y.; Qu, G. Z.; Frady, A.; Varela, M.; Ehrlich, M. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat. Res., 1997, 379, 33-41.
71. Narayan, A.; Ji, W.; Zhang, X. Y.; Marrogi, A.; Graff, J. R.; Baylin, S. B.; Ehrlich, M. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer, 1998, 77, 833-838.
72. Eden, A.; Gaudet, F.; Waghmare, A.; Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 2003, 300, 455.
73. Gaudet, F.; Hodgson, J. G.; Eden, A.; Jackson-Grusby, L.; Dausman, J.; Gray, J. W.; Leonhardt, H.; Jaenisch, R. Induction of tumors in mice by genomic hypomethylation. Science, 2003, 300, 489-492.
74. Pradhan, S.; Bacolla, A.; Wells, R. D.; Roberts, R. J. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J. Biol. Chem., 1999, 274, 33002-33010.
75. Okano, M.; Xie, S.; Li, E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet., 1998, 19, 219-220.
76. Liang, G.; Chan, M. F.; Tomigahara, Y.; Tsai, Y. C.; Gonzales, F. A.; Li, E.; Laird, P. W.; Jones, P. A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell Biol., 2002, 22, 480-491.
77. Vertino, P. M.; Yen, R. W.; Gao, J.; Baylin, S. B. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol. Cell Biol., 1996, 16, 4555-4565.
78. Wu, J.; Issa, J. P.; Herman, J.; Bassett, D. E., Jr.; Nelkin, B. D.; Baylin, S. B. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 1993, 90, 8891-5.
79. Bakin, A. V.; Curran, T. Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science, 1999, 283, 387-390.
80. Eads, C. A.; Nickel, A. E.; Laird, P. W. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res., 2002, 62, 1296-1299.
81. Laird, P. W.; Jackson-Grusby, L.; Fazeli, A.; Dickinson, S. L.; Jung, W. E.; Li, E.; Weinberg, R. A.; Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 1995, 81, 197-205.
82. el-Deiry, W. S.; Nelkin, B. D.; Celano, P.; Yen, R. W.; Falco, J. P.; Hamilton, S. R.; Baylin, S. B. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc. Natl. Acad. Sci. USA, 1991, 88, 3470-3474.
83. Agoston, A. T.; Argani, P.; Yegnasubramanian, S.; De Marzo, A. M.; Ansari-Lari, M. A.; Hicks, J. L.; Davidson, N. E.; Nelson, W. G. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J. Biol. Chem., 2005, 280, 18302-18310.
84. Park, H. J.; Yu, E.; Shim, Y. H. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett., 2006, 233, 271-278.
85. Robert, M. F.; Morin, S.; Beaulieu, N.; Gauthier, F.; Chute, I. C.; Barsalou, A.; MacLeod, A. R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet., 2003, 33, 61-65.
86. Jair, K. W.; Bachman, K. E.; Suzuki, H.; Ting, A. H.; Rhee, I.; Yen, R. W.; Baylin, S. B.; Schuebel, K. E. De novo CpG island methylation in human cancer cells. Cancer Res., 2006, 66, 682-692.
87. Ting, A. H.; Jair, K. W.; Schuebel, K. E.; Baylin, S. B. Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res., 2006, 66, 729-735.
88. Rhee, I.; Bachman, K. E.; Park, B. H.; Jair, K. W.; Yen, R. W.; Schuebel, K. E.; Cui, H.; Feinberg, A. P.; Lengauer, C.; Kinzler, K. W.; Baylin, S. B.; Vogelstein, B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature, 2002, 416, 552-556.
89. Yang, L.; Xia, L.; Wu, D. Y.; Wang, H.; Chansky, H. A.; Schubach, W. H.; Hickstein, D. D.; Zhang, Y. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene, 2002, 21, 148-152.
90. Yang, L.; Mei, Q.; Zielinska-Kwiatkowska, A.; Matsui, Y.; Blackburn, M. L.; Benedetti, D.; Krumm, A. A.; Taborsky, G. J., Jr.; Chansky, H. A. An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem. J., 2003, 369, 651-657.
91. Di Croce, L.; Raker, V. A.; Corsaro, M.; Fazi, F.; Fanelli, M.; Faretta, M.; Fuks, F.; Lo Coco, F.; Kouzarides, T.; Nervi, C.; Minucci, S.; Pelicci, P. G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science, 2002, 295, 1079-1082.
92. Robertson, K. D.; Ait-Si-Ali, S.; Yokochi, T.; Wade, P. A.; Jones, P. L.; Wolffe, A. P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet., 2000, 25, 338-342.
93. Fuks, F.; Burgers, W. A.; Godin, N.; Kasai, M.; Kouzarides, T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J., 2001, 20, 2536-2544.
94. Bachman, K. E.; Park, B. H.; Rhee, I.; Rajagopalan, H.; Herman, J. G.; Baylin, S. B.; Kinzler, K. W.; Vogelstein, B. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell, 2003, 3, 89-95.
95. Rountree, M. R.; Bachman, K. E.; Baylin, S. B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet., 2000, 25, 269-277.
96. Tatematsu, K. I.; Yamazaki, T.; Ishikawa, F. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells, 2000, 5, 677-688.
97. Nguyen, C. T.; Weisenberger, D. J.; Velicescu, M.; Gonzales, F. A.; Lin, J. C.; Liang, G.; Jones, P. A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res., 2002, 62, 6456-6461.
98. McGarvey, K. M.; Fahrner, J. A.; Greene, E.; Martens, J.; Jenuwein, T.; Baylin, S. B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res., 2006, 66, 3541-3549.
99. Esteve, P. O.; Chin, H. G.; Smallwood, A.; Feehery, G. R.; Gangisetty, O.; Karpf, A. R.; Carey, M. F.; Pradhan, S. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev., 2006, 20, 3089-3103.
100. Kim, J. K.; Esteve, P. O.; Jacobsen, S. E.; Pradhan, S. UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res., 2009, 37, 493-505.
101. Smallwood, A.; Esteve, P. O.; Pradhan, S.; Carey, M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev., 2007, 21, 1169-1178.
102. Gazin, C.; Wajapeyee, N.; Gobeil, S.; Virbasius, C. M.; Green, M. R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature, 2007, 449, 1073-1077.
103. Bracken, A. P.; Pasini, D.; Capra, M.; Prosperini, E.; Colli, E.; Helin, K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J., 2003, 22, 5323-5335.
104. Vire, E.; Brenner, C.; Deplus, R.; Blanchon, L.; Fraga, M.; Didelot, C.; Morey, L.; Van Eynde, A.; Bernard, D.; Vanderwinden, J. M.; Bollen, M.; Esteller, M.; Di Croce, L.; de Launoit, Y.; Fuks, F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 2006, 439, 871-874.
105. Egger, G.; Liang, G.; Aparicio, A.; Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429, 457-463.
106. Issa, J. P.; Kantarjian, H. M. Targeting DNA methylation. Clin. Cancer Res., 2009, 15, 3938-3946.
107. Brueckner, B.; Lyko, F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol. Sci., 2004, 25, 551-554.
108. Silverman, L. R.; Demakos, E. P.; Peterson, B. L.; Kornblith, A. B.; Holland, J. C.; Odchimar-Reissig, R.; Stone, R. M.; Nelson, D.; Powell, B. L.; DeCastro, C. M.; Ellerton, J.; Larson, R. A.; Schiffer, C. A.; Holland, J. F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol., 2002, 20, 2429-2440.
109. Wijermans, P.; Lubbert, M.; Verhoef, G.; Bosly, A.; Ravoet, C.; Andre, M.; Ferrant, A. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol., 2000, 18, 956-962.
110. Paz, M. F.; Fraga, M. F.; Avila, S.; Guo, M.; Pollan, M.; Herman, J. G.; Esteller, M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res., 2003, 63, 1114-1121.
111. Villar-Garea, A.; Esteller, M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr. Drug Metab., 2003, 4, 11-31.
112. Cheng, J. C.; Matsen, C. B.; Gonzales, F. A.; Ye, W.; Greer, S.; Marquez, V. E.; Jones, P. A.; Selker, E. U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst., 2003, 95, 399-409.
113. Cheng, J. C.; Yoo, C. B.; Weisenberger, D. J.; Chuang, J.; Wozniak, C.; Liang, G.; Marquez, V. E.; Greer, S.; Orntoft, T. F.; Thykjaer, T.; Jones, P. A. Preferential response of cancer cells to zebularine. Cancer Cell, 2004, 6, 151-158.
114. Laliberte, J.; Marquez, V. E.; Momparler, R. L. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother. Pharmacol., 1992, 30, 7-11.
115. Zhou, L.; Cheng, X.; Connolly, B. A.; Dickman, M. J.; Hurd, P. J.; Hornby, D. P. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol., 2002, 321, 591-599.
116. Segura-Pacheco, B.; Trejo-Becerril, C.; Perez-Cardenas, E.; Taja-Chayeb, L.; Mariscal, I.; Chavez, A.; Acuna, C.; Salazar, A. M.; Lizano, M.; Duenas-Gonzalez, A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res., 2003, 9, 1596-1603.
117. Fang, M. Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C. S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res., 2003, 63, 7563-75670.
118. Brueckner, B.; Boy, R. G.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; Wiessler, M.; Lyko, F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res., 2005, 65, 6305-6311.
119. Yan, L.; Nass, S. J.; Smith, D.; Nelson, W. G.; Herman, J. G.; Davidson, N. E. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther., 2003, 2, 552-556.
120. Jansen, B.; Zangemeister-Wittke, U. Antisense therapy for cancer--the time of truth. Lancet Oncol., 2002, 3, 672-683.
121. Garzon, R.; Fabbri, M.; Cimmino, A.; Calin, G. A.; Croce, C. M. MicroRNA expression and function in cancer. Trends Mol. Med., 2006, 12, 580-587.
122. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C.; Volinia, S.; Guler, G.; Morrison, C. D.; Chan, K. K.; Marcucci, G.; Calin, G. A.; Huebner, K.; Croce, C. M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA, 2007, 104, 15805-15810.
123. Garzon, R.; Liu, S.; Fabbri, M.; Liu, Z.; Heaphy, C. E.; Callegari, E.; Schwind, S.; Pang, J.; Yu, J.; Muthusamy, N.; Havelange, V.; Volinia, S.; Blum, W.; Rush, L. J.; Perrotti, D.; Andreeff, M.; Bloomfield, C. D.; Byrd, J. C.; Chan, K.; Wu, L. C.; Croce, C. M.; Marcucci, G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 2009, 113, 6411-6418.
124. Bots, M.; Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin. Cancer Res., 2009, 15, 3970-3977.
125. Prince, H. M.; Bishton, M. J.; Harrison, S. J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res., 2009, 15, 3958-3969.
126. Schrump, D. S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res., 2009, 15, 3947-3957.
127. Wozniak, R. J.; Klimecki, W. T.; Lau, S. S.; Feinstein, Y.; Futscher, B. W. 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene, 2007, 26, 77-90.
128. Xiong, Y.; Dowdy, S. C.; Podratz, K. C.; Jin, F.; Attewell, J. R.; Eberhardt, N. L.; Jiang, S. W. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res., 2005, 65, 2684-9.
129. Wu, L. P.; Wang, X.; Li, L.; Zhao, Y.; Lu, S.; Yu, Y.; Zhou, W.; Liu, X.; Yang, J.; Zheng, Z.; Zhang, H.; Feng, J.; Yang, Y.; Wang, H.; Zhu, W. G. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell Biol., 2008, 28, 3219-3235.